An Open-Label Study to Evaluate the Efficacy and Safety of Amprenavir (141W94) and Abacavir Combination Therapy in Protease Inhibitor Experienced Subjects With HIV-1 Infection Who Are Failing Their Current Antiretroviral Treatment Regimen

NCT00002205 · clinicaltrials.gov ↗

NA

Phase

COMPLETED

Status

INDUSTRY

Sponsor class

Conditions

HIV Infections

Interventions

DRUG: Abacavir sulfate
DRUG: Amprenavir

Sponsor

Glaxo Wellcome